Post ESMO / WCLC 2019
SCLC en Mesothelioom
Ben van den Borne, longarts
Catharina Ziekenhuis
2
Disclosures
3
Mesothelioom
4
5
6
7
8
Real-world data of nivolumab in
chemotherapy pre-treated
mesothelioma patients
D.W. Dumoulin MDL. Cantini MD, R.A. Belderbos MD, D. Mercieca MD,
R. Cornelissen MD, PhD, J.G.J.V. Aerts, MD, PhD
Erasmus MC
Rotterdam, the Netherlands
n mPFS (months, CI) mOS (months, CI) PR (%) DCR (%)
Nivo-Mes, Quispel, JTO 2018 34 2,6 (2,23-5,49) 11,8 (9,7-15,7) 24 47
MAPS2, Scherpereel, Lancet 2019 63 4,0 (2,8-5,7) 11,9 (6,7-17,7) 19 40
Erasmus MC 59 2,64 (1,56-4,20) 6,36 (4,92-9,12) 12 41
Results
Duration of response in patients with PR:
- Median: not reached
- Mean: 5.86+ months(2.76-10.8+)
Conclusion
In our real world data response rates and OS appears to be lower than in published results.
However, duration of response is clinically meaningful.
Identifying subgroup that is likely to respond is necessary.
DREAM <br /><br />A phase 2 trial of DuRvalumab with first line chEmotherApy in Mesothelioma with a safety run in
Presented By Anna Nowak at 2018 ASCO Annual Meeting
Slide 10
Presented By Anna Nowak at 2018 ASCO Annual Meeting
Progression free survival 6 months = 65% (n=31)
Presented By Anna Nowak at 2018 ASCO Annual Meeting
Slide 17
Presented By Anna Nowak at 2018 ASCO Annual Meeting
Maio, Lancet Oncol 2017; 18: 1261–73
DETERMINE: anti-CTLA4
CTLA4 en PD(L)-1 BlokkadeTremelimumab en durvalumab, fase II
Calabro, Lancet resp 2018
Nivolumab en ipilmumab, fase II (beide)
Disselhorst, Lancet resp 2019
Scherpereel, Lancet oncol 2019
Mediane PFS 6-7 maanden
Checkmate 743
Fase III, 600 patiënten !!
1e lijns chemotherapie vs nivolumab + ipilimumab
Studie een jaar vol, resultaten worden verwacht in 2020
19
Dendritic cell therapy
Tumor cell death and
release of antigen
Dendritic cell engulfs and
presents tumor antigen
T-cell activation
T-cell migration to tumor site
Chen et al. 2013
Cornwall et al. 2016
Proof of concept
Cornelissen, AACR 2019
Dendritic cell therapy: OS of Phase 1 trial
Aerts, CCR 2018
23
NVALT 19
Burgers, ESMO 2019
NVALT 19
Burgers, ESMO 2019
26
SCLC
Systemic therapy advances in SCLC 1985-2019
Ready, JTO 2019
Slide 32
Presented By Christine Hann at 2019 ASCO Annual Meeting
Checkmate 331; Nivolumab vstopotecan
Reck, ESMO IO 2018
Checkmate 331
Reck, ESMO IO 2018
Maintenance
Owonikoko, ELCC 2019
Checkmate 451
Owonikoko, ELCC 2019
Horn, N Engl J Med 2018 IMpower 133
Horn, N Engl J Med 2018 IMpower 133
Paz-Arez, WCLC 2019
Durvalumab plus platinum-etoposide in first-line ED SCLC:
the CASPIAN study
Paz-Arez, WCLC 2019
Durvalumab plus platinum-etoposide in first-line ED SCLC:
the CASPIAN study
IO in LD: Achilles trial
Lurbinectedin
Paz Ares L. ASCO 2019
OS Lurbinectedin
Paz Ares L. ASCO 2019
VRAGEN?